Erice A, Crumpacker C, Britt W, Drew WI, Hillam R, Kao S, Kolberg J, Landry M, Lurain N, Manischewitz J, Nokta M, Spector S, Weinberg A, Yen-Liberman B, Brambilla D, Reichelderfer P; Conference on Retroviruses and Opportunistic Infections.
Program Abstr 3rd Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 3rd 1996 Wash D C. 1996 Jan 28-Feb 1; 3rd: 83.
University of Minnesota, Minneapolis, MN.
CMV is an important pathogen in patients with AIDS and less than 100 CD4 cells/mm3 in whom it causes recurrent end-organ disease, especially retinitis. The presence of CMV in the blood may occur simultaneously or preceding the development of end-organ disease. Recent studies suggest that the amount of CMV (viral load) in peripheral blood leukocyte (PBMC) or plasma (PL) fractions could bean important predicting factor for the development of CMV end-organ disease in patients with AIDS. Standardization of laboratory methods for quantitation of CMV load in PBMC and/or PL fractions would permit identification of patients at risk of developing end-organ disease, evaluation of response to anti-CMV therapies and prediction of clinical relapse. Nine independent laboratories compared several quantitative assays for CMV in PBMC and PL fractions of 15 HIV-infected individuals. Quantitation of CMV load in PBMC fractions was assessed using a CMV antigenemia assay (Incstar) and a branched-DNA assay (Chiron). CMV load in PL fractions was determined using a prototype. quantitative PCR assay (Roche) and a quantitative PCR assay. Results of these evaluations will be presented.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Cytomegalovirus
- Cytomegalovirus Infections
- Cytomegalovirus Retinitis
- HIV Infections
- HIV Seropositivity
- Humans
- Leukocytes
- Polymerase Chain Reaction
- Viral Load
- blood
- methods
- transplantation
Other ID:
UI: 102216217
From Meeting Abstracts